radiolabeled PAN-622 (Sensei Biotherapeutics)

N/A

Report date: 2025/03/20 09:16:28

Base Information

Drug Nameradiolabeled PAN-622 (Sensei Biotherapeutics)

Drug Alias NamePAN-622 mAb-111In conjugateradiolabeled PAN-622 (Panacea)PAN-622 RII[213Bi]-DTPA-PAN-622

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human +[4]

Mechanisms of ActionAspartyl (asparaginyl) β-hydroxylase inhibitors

TargetsAspartyl (asparaginyl) β-hydroxylase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSensei Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSensei Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A